RedHill Biopharma Extends Option Agreement for Phase II-Stage Pancreatic Cancer Drug RP101 RedHill has extended the term of the exclusive option agreement for the oncology drug candidate RP101 for an additional year RP101 is a proprietary, first-in-class, orally-administered,...